| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
3-Deazaadenosine hydrochloride targets S-adenosylhomocysteine hydrolase (SAH hydrolase) with a Ki of 3.9 μM, blocking the hydrolysis of S-adenosylhomocysteine to adenosine and homocysteine, thereby modulating cellular methylation processes and affecting viral RNA methylation, inflammation, and cell proliferation.
|
|---|---|
| ln Vitro |
3-Deazaadenosine has a Ki of 3.9 μM and inhibits the hydrolase of S-adenosylhomocysteine. 3-Deazaadenosine, with an IC50 of 0.15 and 0.20 μM, respectively, shows anti-HIV action and suppresses the p24 antigen in peripheral blood mononuclear (PBMC) cells infected with HIV-1 isolates (A012 and A018) [1]. 3-Deazaadenosine (1-100 μM) causes IκBα (but not IκBβ) to be broken down by proteases, increases the DNA-binding activity of NF-κB, and suppresses the production of TNF-α mRNA in RAW 264.7 cells. 3- Homocysteine increases the inhibitory impact of 3-deazaadenosine (100 μM), which increases NF-κB nuclear translocation but inhibits LPS-induced NF-κB transcriptional activity [2]. 3-Phosphorylation of Raf and ERK, protein-dependent kinase 1, protein kinase B (Akt), and the forkhead transcription factor FoxO1a is dose-dependently inhibited by dexadenosine (50, 100 μM). 3-By blocking Ras signaling, dexaadenosine (50 μM) prevents the growth of vascular smooth muscle cells (VSMCs) [3].
In vitro studies demonstrate that 3-Deazaadenosine hydrochloride inhibits SAH hydrolase with a Ki of 3.9 μM, and exhibits anti-inflammatory properties by inhibiting leukocyte adhesion and chemotaxis, lymphocyte-mediated cytolysis, phagocytosis, degranulation, and NF-κB signaling; it also shows antiviral and antibacterial activities. |
| ln Vivo |
In vivo, 3-Deazaadenosine hydrochloride has been studied for its anti-inflammatory, anti-proliferative, and anti-HIV activities, though detailed in vivo efficacy data are more extensively reported for related compounds; it is used as a tool for studying methylation-dependent biological processes.
|
| Enzyme Assay |
The in vitro enzyme assay for SAH hydrolase inhibition involves incubating 3-Deazaadenosine hydrochloride with purified SAH hydrolase enzyme and adenosine substrate, measuring the conversion of S-adenosylhomocysteine to homocysteine via HPLC or by coupled enzyme assays detecting homocysteine formation, with Ki values calculated from inhibition kinetics.
|
| Cell Assay |
In vitro cell culture studies utilize immune cells (e.g., macrophages, lymphocytes) treated with 3-Deazaadenosine hydrochloride, assessing inflammatory cytokine production by ELISA, cell adhesion by adhesion assays, chemotaxis by Boyden chamber assays, and NF-κB activation by reporter gene assays or Western blotting.
|
| Animal Protocol |
In vivo animal experiments involve administering 3-Deazaadenosine hydrochloride to rodent models of inflammation (e.g., LPS-induced sepsis, carrageenan-induced paw edema) or viral infection, measuring inflammatory markers, viral load, and tissue pathology, with pharmacokinetic parameters assessed in plasma and tissues.
|
| ADME/Pharmacokinetics |
3-Deazaadenosine hydrochloride is a water-soluble adenosine analog with molecular weight 302.71 g/mol; it is typically stored as a powder at -20°C, with solutions stable under recommended conditions; it is also referred to as c3Ado or deaza-Ado.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3-Deazaadenosine hydrochloride are limited to in vitro cytotoxicity assessments; as an adenosine analog affecting methylation, it may have dose-dependent effects on cell viability and proliferation, though comprehensive in vivo toxicity profiles are not extensively reported.
|
| References |
|
| Additional Infomation |
3-Deazaadenosine hydrochloride is a research compound used for studying methylation pathways, viral RNA methylation, inflammatory processes, and cellular signaling; it has been investigated for anti-inflammatory, anti-proliferative, and anti-HIV applications but has not been approved for clinical use.
|
| Molecular Formula |
C11H15CLN4O4
|
|---|---|
| Molecular Weight |
302.714201211929
|
| Exact Mass |
302.078
|
| CAS # |
86583-19-9
|
| Related CAS # |
3-Deazaadenosine;6736-58-9
|
| PubChem CID |
134828261
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C=NC2C(=NC=CC1=2)N.Cl
|
| InChi Key |
WQRKYGAAEYXMKZ-RPWKAPHTSA-N
|
| InChi Code |
InChI=1S/C11H14N4O4.ClH/c12-10-7-5(1-2-13-10)15(4-14-7)11-9(18)8(17)6(3-16)19-11;/h1-2,4,6,8-9,11,16-18H,3H2,(H2,12,13);1H/t6-,8-,9-,11-;/m1./s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-(4-aminoimidazo[4,5-c]pyridin-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~330.35 mM)
DMSO : ~41.67 mg/mL (~137.66 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.87 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.87 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3035 mL | 16.5175 mL | 33.0349 mL | |
| 5 mM | 0.6607 mL | 3.3035 mL | 6.6070 mL | |
| 10 mM | 0.3303 mL | 1.6517 mL | 3.3035 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
